CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Tricida, Inc. - TCDA CFD

0.2334
7.28%
0.0129
Low: 0.2257
High: 0.2413
Market Trading Hours* (UTC) Open now
Closes on Thursday at 21:00

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0129
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 0.2183
Open* 0.2257
1-Year Change* -97.03%
Day's Range* 0.2257 - 0.2257
52 wk Range 0.2053-13.85
Average Volume (10 days) 10.8359
Average Volume (3 months) 163.877
Market Cap 12.0525
P/E Ratio N/A
Shares Outstanding 58028300
Revenue N/A
EPS -2.37405
Dividend (Yield %) N/A
Beta 0.09335
Next Earnings Date Mar 27, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Nov 30, 2022 0.2183 -0.0402 -15.55% 0.2585 0.2606 0.2166
Nov 29, 2022 0.2651 -0.0091 -3.32% 0.2742 0.2791 0.2350
Nov 28, 2022 0.2606 0.0407 18.51% 0.2199 0.2875 0.2139
Nov 25, 2022 0.2002 0.0002 0.10% 0.2000 0.2383 0.1958
Nov 23, 2022 0.2003 -0.0280 -12.26% 0.2283 0.2596 0.2003
Nov 22, 2022 0.2023 -0.0251 -11.04% 0.2274 0.2310 0.2010
Nov 21, 2022 0.2181 -0.0257 -10.54% 0.2438 0.2447 0.2181
Nov 18, 2022 0.2475 -0.0131 -5.03% 0.2606 0.2645 0.2350
Nov 17, 2022 0.2577 0.0226 9.61% 0.2351 0.2660 0.2320
Nov 16, 2022 0.2355 0.0007 0.30% 0.2348 0.2510 0.2153
Nov 15, 2022 0.2351 -0.0289 -10.95% 0.2640 0.2740 0.2153
Nov 14, 2022 0.2597 0.0052 2.04% 0.2545 0.3165 0.2352
Nov 11, 2022 0.2547 0.0185 7.83% 0.2362 0.2832 0.2259
Nov 10, 2022 0.2246 -0.0017 -0.75% 0.2263 0.2473 0.2154
Nov 9, 2022 0.2131 -0.0351 -14.14% 0.2482 0.2548 0.2131
Nov 8, 2022 0.2548 -0.0281 -9.93% 0.2829 0.2830 0.2547
Nov 7, 2022 0.2777 0.0138 5.23% 0.2639 0.2900 0.2526
Nov 4, 2022 0.2772 0.0100 3.74% 0.2672 0.2971 0.2473
Nov 3, 2022 0.2686 -0.0015 -0.56% 0.2701 0.2755 0.2430
Nov 2, 2022 0.2721 -0.0320 -10.52% 0.3041 0.3074 0.2692

Tricida, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 0 0 0 0 0 0
Total Operating Expense 27.183 47.122 103.595 178.824 251.4 159.078
Selling/General/Admin. Expenses, Total 5.363 11.216 18.001 45.796 102.983 37.59
Research & Development 21.82 35.906 85.594 133.028 148.417 115.364
Operating Income -27.183 -47.122 -103.595 -178.824 -251.4 -159.078
Interest Income (Expense), Net Non-Operating -1.468 5.832 -3.137 -5.744 -18.407 -17.102
Net Income Before Taxes -28.651 -41.29 -102.808 -176.905 -264.791 -176.566
Net Income After Taxes -28.651 -41.29 -102.808 -176.813 -264.791 -176.566
Net Income Before Extra. Items -28.651 -41.29 -102.808 -176.813 -264.791 -176.566
Net Income -28.651 -41.29 -102.808 -176.813 -264.791 -176.566
Income Available to Common Excl. Extra. Items -28.651 -41.29 -102.808 -176.813 -264.791 -176.566
Income Available to Common Incl. Extra. Items -28.651 -41.29 -102.808 -176.813 -264.791 -176.566
Diluted Net Income -28.651 -41.29 -102.808 -176.813 -264.791 -176.566
Diluted Weighted Average Shares 40.1894 40.1894 42.3862 47.5212 50.0277 51.2807
Diluted EPS Excluding Extraordinary Items -0.7129 -1.02738 -2.42551 -3.72072 -5.29288 -3.44313
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.7129 -1.02738 -2.42551 -3.72072 -5.29164 -3.32371
Other, Net 3.924 7.663 5.016 -0.386
Unusual Expense (Income) 6.124
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 0 0 0 0 0
Total Operating Expense 48.194 29.331 35.687 45.866 27.674
Selling/General/Admin. Expenses, Total 9.895 9.55 9.052 9.093 9.17
Research & Development 32.175 19.781 26.635 36.773 18.504
Unusual Expense (Income) 6.124 0 0 0 0
Operating Income -48.194 -29.331 -35.687 -45.866 -27.674
Interest Income (Expense), Net Non-Operating -5.613 -3.926 -3.994 -4.069 -1.973
Other, Net 0.445 -0.296 0.006 -0.041 0.008
Net Income Before Taxes -53.362 -33.553 -39.675 -49.976 -29.639
Net Income After Taxes -53.362 -33.553 -39.675 -49.976 -29.639
Net Income Before Extra. Items -53.362 -33.553 -39.675 -49.976 -29.639
Net Income -53.362 -33.553 -39.675 -49.976 -29.639
Income Available to Common Excl. Extra. Items -53.362 -33.553 -39.675 -49.976 -29.639
Income Available to Common Incl. Extra. Items -53.362 -33.553 -39.675 -49.976 -29.639
Diluted Net Income -53.362 -33.553 -39.675 -49.976 -29.639
Diluted Weighted Average Shares 50.2477 50.2948 50.4349 54.1434 57.719
Diluted EPS Excluding Extraordinary Items -1.06198 -0.66713 -0.78666 -0.92303 -0.51351
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.9401 -0.66912 -0.78666 -0.92303 -0.51351
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 27.203 69.424 244.347 312.742 314.015 145.536
Cash and Short Term Investments 26.45 67.514 241.078 307.998 309.527 140.532
Cash & Equivalents 5.682 9.774 37.172 18.574 137.857 21.113
Short Term Investments 20.768 57.74 203.906 289.424 171.67 119.419
Prepaid Expenses 0.753 1.91 3.269 4.744 4.488 5.004
Total Assets 27.684 70.574 247.849 371.826 351.685 168.506
Property/Plant/Equipment, Total - Net 0.481 1.15 1.215 12.104 14.913 12.927
Property/Plant/Equipment, Total - Gross 1.449 2.453 3.136 14.752 19.138 17.448
Accumulated Depreciation, Total -0.968 -1.303 -1.921 -2.648 -4.225 -4.521
Total Current Liabilities 8.24 11.222 14.804 39.763 34.258 29.48
Accounts Payable 2.104 3.861 8.46 5.911 3.508 10.023
Accrued Expenses 2.765 7.361 6.344 33.852 30.75 19.457
Notes Payable/Short Term Debt 3.371 0 0 0 0 0
Total Liabilities 8.429 11.545 53.324 107.943 242.814 168.288
Total Long Term Debt 0 0 38.071 58.374 195.308 127.512
Other Liabilities, Total 0.189 0.323 0.449 9.806 13.248 11.296
Total Equity 19.255 59.029 194.525 263.883 108.871 0.218
Redeemable Preferred Stock 0 0 0 0 0
Preferred Stock - Non Redeemable, Net 66.883 147.07
Common Stock 0.002 0.002 0.042 0.05 0.05 0.055
Additional Paid-In Capital 0.466 1.356 386.83 632.647 742.555 810.618
Retained Earnings (Accumulated Deficit) -48.096 -89.386 -192.194 -369.007 -633.798 -810.364
Unrealized Gain (Loss) 0 -0.013 -0.153 0.193 0.064 -0.091
Total Liabilities & Shareholders’ Equity 27.684 70.574 247.849 371.826 351.685 168.506
Total Common Shares Outstanding 40.1894 40.1894 42.1483 49.7632 50.2108 55.3635
Long Term Investments 2.287 46.98 22.757 10.043
Long Term Debt 38.071 58.374 195.308 127.512
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 220.72 181.027 151.174 145.536 127.995
Cash and Short Term Investments 217.731 175.766 146.77 140.532 123.726
Cash & Equivalents 40.51 22.865 16.988 21.113 17.712
Short Term Investments 177.221 152.901 129.782 119.419 106.014
Prepaid Expenses 2.989 5.261 4.404 5.004 4.269
Total Assets 235.168 194.948 164.586 168.506 140.414
Property/Plant/Equipment, Total - Net 14.448 13.921 13.412 12.927 12.419
Long Term Investments 0 0 0 10.043 0
Total Current Liabilities 40.205 24.868 25.731 29.48 24.994
Accounts Payable 5.321 2.738 3.261 10.023 5.535
Accrued Expenses 34.884 22.13 22.47 19.457 19.459
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 173.607 160.019 162.684 168.288 230.714
Total Long Term Debt 120.775 122.951 125.194 127.512 194.894
Long Term Debt 120.775 122.951 125.194 127.512 194.894
Other Liabilities, Total 12.627 12.2 11.759 11.296 10.826
Total Equity 61.561 34.929 1.902 0.218 -90.3
Common Stock 0.05 0.05 0.05 0.055 0.055
Additional Paid-In Capital 748.712 755.654 762.317 810.618 737.685
Retained Earnings (Accumulated Deficit) -687.16 -720.713 -760.388 -810.364 -827.663
Unrealized Gain (Loss) -0.041 -0.062 -0.077 -0.091 -0.377
Total Liabilities & Shareholders’ Equity 235.168 194.948 164.586 168.506 140.414
Total Common Shares Outstanding 50.2727 50.4287 50.4476 55.3635 55.3972
Redeemable Preferred Stock 0 0
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -28.651 -41.29 -102.808 -176.813 -264.791 -176.566
Cash From Operating Activities -23.115 -40.401 -94.856 -129.59 -231.187 -140.056
Cash From Operating Activities 0.424 0.335 0.618 0.757 0.897 0.442
Non-Cash Items 1.857 -4.815 5.186 25.331 37.272 42.183
Changes in Working Capital 3.255 5.369 2.148 21.135 -4.565 -6.115
Cash From Investing Activities -20.281 -37.947 -148.354 -127.498 140.277 64.218
Capital Expenditures -0.249 -1.004 -0.855 -1.423 -1.605 -0.099
Other Investing Cash Flow Items, Total -20.032 -36.943 -147.499 -126.075 141.882 64.317
Cash From Financing Activities 42.973 82.44 270.608 238.49 210.193 -40.906
Issuance (Retirement) of Stock, Net 43.015 82.479 238.467 220.966 2.017 42.417
Issuance (Retirement) of Debt, Net -0.042 -0.039 38.705 18.445 208.176 -83.323
Net Change in Cash -0.423 4.092 27.398 -18.598 119.283 -116.744
Cash Interest Paid 1.612 3.348 9.084 8.774
Financing Cash Flow Items -6.564 -0.921 0
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -53.362 -86.915 -126.59 -176.566 -29.639
Cash From Operating Activities -30.978 -73.107 -101.996 -140.056 -26.402
Cash From Operating Activities 0.134 0.253 0.351 0.442 0.081
Non-Cash Items 15.02 24.179 33.254 42.183 6.694
Cash Interest Paid 1.774 5.274 5.274 8.774 0
Changes in Working Capital 7.23 -10.624 -9.011 -6.115 -3.538
Cash From Investing Activities 16.816 40.99 63.988 64.218 23.191
Capital Expenditures -0.076 -0.076 -0.076 -0.099 0
Other Investing Cash Flow Items, Total 16.892 41.066 64.064 64.317 23.191
Cash From Financing Activities -83.185 -82.875 -82.861 -40.906 -0.19
Issuance (Retirement) of Stock, Net 0.115 0.448 0.462 42.417 0.008
Issuance (Retirement) of Debt, Net -83.3 -83.323 -83.323 -83.323 0
Net Change in Cash -97.347 -114.992 -120.869 -116.744 -3.401
Financing Cash Flow Items -0.198

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Tricida Company profile

About Tricida Inc

Tricida, Inc. is a pharmaceutical company, which is focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101). TRC101, is a non-absorbed, orally administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Its Veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. Its VALOR-CKD trial is a randomized, double-blind, placebo-controlled, time-to-event trial.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Tricida Inc revenues was not reported. Net loss decreased 40% to $126.6M. Lower net loss reflects General and administrative - Balancing decrease of 81% to $12.6M (expense), Research and development - Balancing val decrease of 42% to $64.7M (expense), Stock-Based Compensation decrease of 28% to $11.4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$4.20 to -$2.52.

Industry: Biotechnology & Medical Research (NEC)

7000 Shoreline Court, Suite 201
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

People also watch

XRP/USD

0.40 Price
-3.380% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00317

Oil - Crude

82.81 Price
+2.730% 1D Chg, %
Long position overnight fee -0.0094%
Short position overnight fee -0.0042%
Overnight fee time 22:00 (UTC)
Spread 0.03

US100

12,018.10 Price
-0.330% 1D Chg, %
Long position overnight fee -0.0159%
Short position overnight fee 0.0057%
Overnight fee time 22:00 (UTC)
Spread 1.8

Natural Gas

6.88 Price
-0.920% 1D Chg, %
Long position overnight fee 0.0480%
Short position overnight fee -0.0742%
Overnight fee time 22:00 (UTC)
Spread 0.005

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading